Millennium Management
CERE

Millennium Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Millennium Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,004,795
Closed -$82M – 6655
2024
Q2 		$82M Buy
2,004,795
+531,972
+36% +$22.2M 0.04% 511
2024
Q1 		$62.3M Buy
1,472,823
+361,711
+33% +$15.2M 0.03% 698
2023
Q4 		$47.1M Sell
1,111,112
-1,018,701
-48% -$29.3M 0.02% 843
2023
Q3 		$46.5M Buy
2,129,813
+1,950,018
+1,085% +$48.8M 0.02% 756
2023
Q2 		$5.72M Sell
179,795
-285,195
-61% -$8.75M ﹤0.01% 2557
2023
Q1 		$11.3M Buy
+464,990
New +$13.6M 0.01% 1831
2022
Q2 		– Sell
-45,371
Closed -$1.29M – 7662
2022
Q1 		$1.59M Sell
45,371
-15,231
-25% -$445K ﹤0.01% 4084
2021
Q4 		$1.97M Buy
60,602
+48,332
+394% +$1.71M ﹤0.01% 3795
2021
Q3 		$362K Buy
+12,270
New +$344K ﹤0.01% 5662
2021
Q2 		– Sell
-426,016
Closed -$5.85M – 7258
2021
Q1 		$5.85M Buy
426,016
+386,444
+977% +$5.65M ﹤0.01% 2404
2020
Q4 		$656K Buy
+39,572
New +$514K ﹤0.01% 4008

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Millennium Management's CERE Position: Q3 2024 in Review

Millennium Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,004,795 shares — an estimated $82M sold.

Millennium Management first reported a position in CERE in Q4 2020 and held it in 11 quarters. The position peaked at $82M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Millennium Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Millennium Management sold 2,004,795 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $82M.
  • Millennium Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
  • Millennium Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $82M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Millennium Management's 13F filing for Q3 2024, filed 14 Nov 2024.